Healthcare shares are flat in pre-market trade.
Oramed Pharmaceuticals (
) was down about 16% in pre-market trade after the developer of
oral drug delivery systems said it entered into definitive
agreements with investors to purchase an aggregate of 1,580,000
shares of common stock at a price of $10.00 per share in a
registered direct offering.
And bluebird bio, Inc. (
) a clinical-stage company that develops potentially transformative
gene therapies for severe genetic and orphan diseases, was recently
added to the NASDAQ Biotechnology Index effective prior to the
market open on December 23, 2013.
Finally, DS Healthcare (
) said Thursday that it has entered and consummated a securities
purchase agreement with an accredited investor for the sale of
1.512 million shares of the company's common stock, with gross
proceeds of $2.42 million.
The shares were offered and sold solely to accredited investors
on a private placement basis. Shares closed at $2.30 with a 52-week
range of $1.41 - $3.94.
Copyright (C) 2014 MTNewswires.com. All rights reserved. Unauthorized reproduction is strictly prohibited.